HC Wainwright Reduces Earnings Estimates for Adicet Bio

Adicet Bio, Inc. (NASDAQ:ACET) – Equities researchers at HC Wainwright decreased their FY2025 earnings per share estimates for Adicet Bio in a report released on Wednesday, January 21st. HC Wainwright analyst R. Burns now anticipates that the company will earn ($18.36) per share for the year, down from their prior forecast of ($18.08). HC Wainwright has a “Buy” rating and a $50.00 price objective on the stock. The consensus estimate for Adicet Bio’s current full-year earnings is ($1.39) per share. HC Wainwright also issued estimates for Adicet Bio’s Q4 2025 earnings at ($3.59) EPS, Q1 2026 earnings at ($2.91) EPS, Q2 2026 earnings at ($3.00) EPS, Q3 2026 earnings at ($3.08) EPS, Q4 2026 earnings at ($3.17) EPS and FY2026 earnings at ($12.17) EPS.

Several other equities research analysts also recently issued reports on the company. Citigroup reaffirmed a “market perform” rating on shares of Adicet Bio in a research report on Wednesday, November 19th. Wedbush reaffirmed an “outperform” rating and issued a $80.00 price target on shares of Adicet Bio in a research report on Thursday, November 6th. Jefferies Financial Group upgraded Adicet Bio to a “strong-buy” rating in a report on Tuesday, October 7th. Weiss Ratings restated a “sell (d-)” rating on shares of Adicet Bio in a research note on Thursday, October 30th. Finally, Guggenheim upped their target price on shares of Adicet Bio from $112.00 to $128.00 and gave the company a “buy” rating in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Adicet Bio presently has an average rating of “Moderate Buy” and an average price target of $69.00.

Adicet Bio Stock Performance

Shares of ACET opened at $8.40 on Friday. The company has a market capitalization of $80.47 million, a PE ratio of -0.42 and a beta of 1.60. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.62 and a quick ratio of 5.62. Adicet Bio has a one year low of $7.15 and a one year high of $17.44. The company’s fifty day moving average price is $8.55 and its 200 day moving average price is $11.06.

Adicet Bio (NASDAQ:ACET) last released its quarterly earnings results on Wednesday, November 5th. The company reported ($4.64) EPS for the quarter, missing analysts’ consensus estimates of ($4.16) by ($0.48).

Institutional Investors Weigh In On Adicet Bio

A number of institutional investors have recently bought and sold shares of ACET. Goldman Sachs Group Inc. raised its stake in shares of Adicet Bio by 1.7% in the 1st quarter. Goldman Sachs Group Inc. now owns 3,816,556 shares of the company’s stock valued at $2,882,000 after buying an additional 63,691 shares in the last quarter. Vontobel Holding Ltd. grew its stake in Adicet Bio by 33.3% during the second quarter. Vontobel Holding Ltd. now owns 80,000 shares of the company’s stock worth $49,000 after buying an additional 20,000 shares during the last quarter. Wealthedge Investment Advisors LLC increased its holdings in shares of Adicet Bio by 37.4% during the second quarter. Wealthedge Investment Advisors LLC now owns 313,108 shares of the company’s stock worth $191,000 after buying an additional 85,307 shares in the last quarter. Squarepoint Ops LLC bought a new position in shares of Adicet Bio in the third quarter valued at approximately $38,000. Finally, Two Sigma Investments LP boosted its holdings in shares of Adicet Bio by 66.6% in the 3rd quarter. Two Sigma Investments LP now owns 854,568 shares of the company’s stock worth $692,000 after acquiring an additional 341,761 shares in the last quarter. Institutional investors and hedge funds own 83.89% of the company’s stock.

Adicet Bio Company Profile

Adicet Bio, Inc (NASDAQ: ACET) is a clinical?stage biotechnology company specializing in the development of off?the?shelf, allogeneic gamma delta (??) T cell therapies for oncology and autoimmune disorders. The company’s proprietary platform enables the genetic engineering of ?? T cells with chimeric antigen receptors (CARs) and other molecular modifications to enhance tumor targeting, expansion, and persistence. By leveraging the innate tumor-recognition properties of ?? T cells, Adicet seeks to overcome the manufacturing and safety challenges associated with autologous cell therapies.

Adicet’s lead product candidate, ADI-001, is a CAR?engineered allogeneic ?? T cell therapy directed against CD20 for the treatment of relapsed or refractory B-cell malignancies.